Anthropic is acquiring Coefficient Bio — a New York startup operating in near-total stealth — for roughly $400 million, according to The Information. That’s $40 million or more per employee.
Coefficient’s website is blank. Its LinkedIn page lists a handful of names. BioSpace’s inquiry email bounced. The exact deal value wasn’t disclosed, and neither was a closing timeline.
What Anthropic’s actually buying is murky. Coefficient’s co-founders, Nathan Frey and Samuel Stanton, both built ML systems at Genentech. Stanton is already on Anthropic’s technical staff. CEO Aris Theologis previously ran teams at Evozyne and Paragon Biosciences. Nobody’s saying what the platform does.
Anthropic launched Claude Life Sciences in October 2025, targeting biopharma scientists and regulatory managers. Sanofi, Novo Nordisk, and AbbVie are already customers. Coefficient folds into that healthcare team.
The valuation logic is the real story. At $400M for a sub-10-person stealth shop, Anthropic isn’t buying revenue — it’s buying whatever IP two ex-Genentech ML engineers built quietly for the past few years. Compare that to Eli Lilly’s $2.75B deal with Insilico Medicine last week, which at least named a use case. Coefficient has none of that on record.
If a company nobody’s heard of commands $400M, every pharma AI acqui-hire just got pricier.
— Diana Kowalski